FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022290094> ?p ?o ?g. }

• W2022290094 endingPage "63" @default.
• W2022290094 startingPage "57" @default.
• W2022290094 abstract "This study was designed to evaluate a combined modality treatment for malignant gliomas using radiation therapy with a radiosensitizer and an adjuvant chemotherapy regimen designed to modify resistance to BNCU.Patients were eligible if they were 15 years of age or older, and had newly diagnosed glioblastoma multiforme (GBM), or anaplastic glioma (AG). Treatment consisted of external beam radiotherapy given to a dose of 60 Gy using a single daily fraction Monday to Friday. Concurrent hydroxyurea at a dose of 300 mg/m2 every 6 h every other day was given during radiation. Following radiotherapy, patients were then treated with BCNU and 6-Thioguanine (6TG). The 6-TG was given by mouth every 6 h for 12 doses prior to BCNU. Patients were initially treated with 60 mg/m2/dose of 6TG, with escalation to a maximum dose of 100 mg/m2/dose. The primary study end points were time to tumor progression and survival.A total of 245 eligible patients were enrolled from 1/18/88 to 12/26/91. The histologic subtypes included 135 GBM, and 110 with AG (103 with anaplastic astrocytoma, 7 with high-grade mixed oligoastrocytoma). For the GBM group, the median time to tumor progression (TTP) and median survival were 33 (95% CI 26, 39) and 56 (95% CI 49, 69) weeks, respectively. For the AG group the median TTP was 282 weeks (95% lower confidence bound = 155 weeks). Median survival for this group has not been reached (95% lower confidence bound = 284 weeks) with a median follow-up for surviving patients of 298 weeks. A proportional hazards model was used to look at potential prognostic factors for survival, including initial Karnofsky Performance Scale (KPS), age, and extent of surgery, as well as dose of 6TG. Higher KPS, and lower age, predicted for longer survival (p < 0.01, < 0.001) in GBM patients; lower age was significant (p = 0.05) for AG cases. A higher (greater than 95 mg/m2) or lower dose of 6TG was not statistically significant in this model.This therapy was no more effective in patients with GBM than other reported series. In patients with malignant gliomas other than GBM, prolonged progression-free and overall survival is noted, without a median survival reached at the time of this report. In this subset of AG patients, survival is comparable to recent studies using halogenated prymidines during radiation and Procarbazine, CCNU, and Vincristine (PCV) as adjuvant chemotherapy." @default.
• W2022290094 created "2016-06-24" @default.
• W2022290094 creator A5001979226 @default.
• W2022290094 creator A5004126746 @default.
• W2022290094 creator A5015766907 @default.
• W2022290094 creator A5019327576 @default.
• W2022290094 creator A5030052480 @default.
• W2022290094 creator A5039465135 @default.
• W2022290094 creator A5042076336 @default.
• W2022290094 creator A5044634523 @default.
• W2022290094 creator A5046264008 @default.
• W2022290094 creator A5051168746 @default.
• W2022290094 creator A5057121260 @default.
• W2022290094 creator A5061018141 @default.
• W2022290094 creator A5062086025 @default.
• W2022290094 creator A5063459903 @default.
• W2022290094 creator A5065718203 @default.
• W2022290094 creator A5071361060 @default.
• W2022290094 creator A5073984522 @default.
• W2022290094 creator A5088040279 @default.
• W2022290094 date "1998-01-01" @default.
• W2022290094 modified "2023-09-26" @default.
• W2022290094 title "Radiation Therapy and Hydroxyurea Followed by the Combination of 6-Thioguanine and BCNU for the Treatment of Primary Malignant Brain Tumors" @default.
• W2022290094 cites W1868719232 @default.
• W2022290094 cites W1964649473 @default.
• W2022290094 cites W1972587438 @default.
• W2022290094 cites W1976935937 @default.
• W2022290094 cites W1984032366 @default.
• W2022290094 cites W1984329749 @default.
• W2022290094 cites W1988443774 @default.
• W2022290094 cites W2028037535 @default.
• W2022290094 cites W2036034721 @default.
• W2022290094 cites W2042341862 @default.
• W2022290094 cites W2058250823 @default.
• W2022290094 cites W2110646834 @default.
• W2022290094 cites W2119948322 @default.
• W2022290094 cites W2155317776 @default.
• W2022290094 cites W2163342290 @default.
• W2022290094 cites W2167836234 @default.
• W2022290094 cites W2168167387 @default.
• W2022290094 doi "https://doi.org/10.1016/s0360-3016(97)00566-x" @default.
• W2022290094 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9422558" @default.
• W2022290094 hasPublicationYear "1998" @default.
• W2022290094 type Work @default.
• W2022290094 sameAs 2022290094 @default.
• W2022290094 citedByCount "60" @default.
• W2022290094 countsByYear W20222900942012 @default.
• W2022290094 countsByYear W20222900942015 @default.
• W2022290094 countsByYear W20222900942016 @default.
• W2022290094 countsByYear W20222900942018 @default.
• W2022290094 countsByYear W20222900942020 @default.
• W2022290094 countsByYear W20222900942022 @default.
• W2022290094 crossrefType "journal-article" @default.
• W2022290094 hasAuthorship W2022290094A5001979226 @default.
• W2022290094 hasAuthorship W2022290094A5004126746 @default.
• W2022290094 hasAuthorship W2022290094A5015766907 @default.
• W2022290094 hasAuthorship W2022290094A5019327576 @default.
• W2022290094 hasAuthorship W2022290094A5030052480 @default.
• W2022290094 hasAuthorship W2022290094A5039465135 @default.
• W2022290094 hasAuthorship W2022290094A5042076336 @default.
• W2022290094 hasAuthorship W2022290094A5044634523 @default.
• W2022290094 hasAuthorship W2022290094A5046264008 @default.
• W2022290094 hasAuthorship W2022290094A5051168746 @default.
• W2022290094 hasAuthorship W2022290094A5057121260 @default.
• W2022290094 hasAuthorship W2022290094A5061018141 @default.
• W2022290094 hasAuthorship W2022290094A5062086025 @default.
• W2022290094 hasAuthorship W2022290094A5063459903 @default.
• W2022290094 hasAuthorship W2022290094A5065718203 @default.
• W2022290094 hasAuthorship W2022290094A5071361060 @default.
• W2022290094 hasAuthorship W2022290094A5073984522 @default.
• W2022290094 hasAuthorship W2022290094A5088040279 @default.
• W2022290094 hasConcept C126322002 @default.
• W2022290094 hasConcept C141071460 @default.
• W2022290094 hasConcept C143998085 @default.
• W2022290094 hasConcept C2776428644 @default.
• W2022290094 hasConcept C2776694085 @default.
• W2022290094 hasConcept C2776755627 @default.
• W2022290094 hasConcept C2778227246 @default.
• W2022290094 hasConcept C2778880634 @default.
• W2022290094 hasConcept C2779083369 @default.
• W2022290094 hasConcept C2779429289 @default.
• W2022290094 hasConcept C2779434656 @default.
• W2022290094 hasConcept C2781413609 @default.
• W2022290094 hasConcept C2989005 @default.
• W2022290094 hasConcept C44249647 @default.
• W2022290094 hasConcept C502942594 @default.
• W2022290094 hasConcept C509974204 @default.
• W2022290094 hasConcept C71924100 @default.
• W2022290094 hasConcept C90924648 @default.
• W2022290094 hasConceptScore W2022290094C126322002 @default.
• W2022290094 hasConceptScore W2022290094C141071460 @default.
• W2022290094 hasConceptScore W2022290094C143998085 @default.
• W2022290094 hasConceptScore W2022290094C2776428644 @default.
• W2022290094 hasConceptScore W2022290094C2776694085 @default.
• W2022290094 hasConceptScore W2022290094C2776755627 @default.
• W2022290094 hasConceptScore W2022290094C2778227246 @default.
• W2022290094 hasConceptScore W2022290094C2778880634 @default.
• W2022290094 hasConceptScore W2022290094C2779083369 @default.

• next